Phase 1 study of venetoclax/azacitidine or venetoclax in combination with ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) chemotherapy in combination with ziftomenib for the treatment of patients with acute myeloid leukemia
Primary Objective
To determine the safety and tolerability of ziftomenib combined with SOC treatments in adults with newly diagnosed NPM1-m or KMT2A-r AML and for ziftomenib combined with SOC treatments in NPM1-m or KMT2A-r patients with relapsed or refractory AML
Details
Age
Adult
Type of Study
Treatment
Locations
CTRC Inpatient
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Christine Mcmahon, MD
Study ID
Protocol Number: 23-0061
More information available at ClinicalTrials.gov: NCT05735184
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers